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Abstract
Objective: Patients treated for nonfunctioning pituitary macroadenoma (NFMA) with suprasellar extension show disturbed
sleep characteristics, possibly related to hypothalamic dysfunction. In addition to hypopituitarism, both structural
hypothalamic damage and sleep restriction per se are associated with the metabolic syndrome. However, the prevalence of
the metabolic syndrome in patients with NFMA is not well established. Our objective was to study the prevalence and risk
factors for (components of) the metabolic syndrome in patients treated for NFMA.
Design: The metabolic syndrome (NCEP-ATP III criteria) was studied in an unselected cohort of 145 NFMA patients (aged
26–88yr, 44% female) in long-term remission after treatment, receiving adequate stable hormone replacement for any
pituitary deficiencies. The results were compared to population data of 63,995 Dutch inhabitants by standardization
(LifeLines cohort study).
Results: NFMA patients showed increased risk for reduced HDL-cholesterol (SMR 1.59, 95% CI 1.13–2.11), increased
triglyceride levels (SMR 2.31, 95% CI 1.78–2.90) and the metabolic syndrome (SMR 1.60, 95% CI 1.22–2.02), but not for
increased blood pressure, waist circumference or hyperglycemia. Preoperative visual field defects independently affected
the risk for increased blood pressure (OR 6.5, 95% CI 1.9–22.2), and hypopituitarism was associated with a body mass index -
dependent risk for increased waist circumference (OR 1.6, 95% CI 1.2–2.2) and the metabolic syndrome (OR 1.4, 95% CI
1.0–1.9).
Conclusions: Patients treated for NFMA are increased at risk for developing the metabolic syndrome, mainly due to
decreased HDL-cholesterol and increased triglycerides. Risk factors included hypopituitarism and preoperative visual field
defects. Hypothalamic dysfunction may explain the metabolic abnormalities, in addition to intrinsic imperfections of
hormone replacement therapy. Additional research is required to explore the relation between derangements in circadian
rhythmicity and metabolic syndrome in these patients.
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Nonfunctioning pituitary macroadenomas (NFMA, adenoma
.10 mm) comprise approximately 25% of clinically relevant
pituitary adenomas [1], and often present with pituitary insuffi-
ciency and visual field defects (VFD) due to compression of the
optic chiasm. Transsphenoidal surgery is the treatment of choice,
resulting in improvement of visual function in the majority of
patients [2]. Selected patients require treatment by postoperative
radiotherapy [3]. In follow-up, a high prevalence of hypopituita-
rism remains present in NFMA patients.
Previously, we have shown that patients successfully treated for
NFMA suffer from disturbances in sleep characteristics, circadian
movement rhythm, and subjective sleep quality [4], the cause of
which remains to be elucidated. In view of the close anatomical
relationship between the optic chiasm and the hypothalamus, it is
possible that impaired function of the suprachiasmatic nucleus
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(SCN) of the hypothalamus, the main director of circadian
rhythmicity, might cause these symptoms.
Besides the decreased quality of life that was associated with
these sleeping difficulties [4], the clinical relevance and conse-
quences of possible circadian dysregulation in NFMA patients
might be further underlined and assessed by an increased risk for
cardiovascular disease. Circadian dysregulation due to hypotha-
lamic damage is associated with the metabolic syndrome both
directly, a syndrome known as hypothalamic obesity after
structural hypothalamic damage [5], and indirectly, through the
consequences of decreased sleep duration and quality [6]. In
addition, intrinsic imperfections of hormone replacement therapy
might increase the risk for the metabolic syndrome in NFMA
patients.
To date, most studies on metabolic features in patients with
pituitary diseases were performed in heterogeneous patient groups
with either hormone excess syndromes or GH deficiency (GHD),
which makes it cumbersome to explore potential hypothalamic
effects of pituitary tumors. Therefore, in the present study, we
studied the metabolic syndrome and its individual components in
an unselected cohort of patients treated for NFMA, and compared




The Medical Ethics Committee of the Leiden University
Medical Center issued a statement of no objection. Patients gave
written consent for the collection of data from outside our hospital.
Study design
In this controlled cross-sectional study, the prevalence of the
metabolic syndrome and its components were studied in an
unselected cohort of 145 patients treated for NFMA, and
compared to population based normative data of 63,995 Dutch
inhabitants by standardization (LifeLines cohort study).
Subjects
NFMA Patients. Based on a clinical database of 226 patients
consecutively treated for NFMA at our center between 1980 and
2010, data and parameters of the metabolic syndrome were
collected from clinical records. Patients were included when a)
treated for NFMA via transsphenoidal surgery, b) any anterior
pituitary hormone deficiencies were adequately and stably
substituted (vide infra), and c) data on all parameters of the
metabolic syndrome was retrievable. 81 patients (36%) were
excluded due to missing data. The excluded patients did not differ
statistically significant from the included patients, except for fewer
cases of radiotherapy and generally a higher age in excluded
patients.
The NFMA was staged according to Wilson’s modification of
the classification by Hardy [7]. VFD were diagnosed by standard
Goldmann perimetry and evaluated by an ophthalmologist.
Patients were routinely evaluated every year, and data from the
most recent visit were used. Eleven patients were followed yearly
in other hospitals, and their data were obtained from treating
physicians. In 10 deceased patients, data from their last visit were
used.
ACTH deficiency was defined as an insufficient increase in
cortisol levels (,0.55 mmol/liter) after a CRH stimulation test or
insulin tolerance test. TSH deficiency was defined as free T4 levels
below the reference range (,10 pmol/L). Hypogonadism was
defined as low testosterone levels (,8.0 nmol/liter) in men, and
absence of menstrual cycle for more than one year in the presence
of low estrogen levels in premenopausal women. GHD was
defined as a GH peak response to the insulin tolerance test (ITT)
below 3mg/liter (glucose nadir ,2.2 mmol/liter) or GH releasing
hormone - arginine test [with body mass index (BMI) – adjusted
GH cutoffs] in case of contraindications for ITT, according to
guidelines [8]. Data from the most recent hormonal axis
evaluation were used. Hypopituitarism was supplemented by
hydrocortisone, levothyroxine, recombinant human GH (rhGH,
unless contraindicated or not preferred), testosterone in men, and
estrogen in combination with prostagens in premenopausal
women. Dosages were monitored and adjusted as required, and
stable substitution was assumed if medication was not adjusted for
6 months, complaints were absent, and basal hormone levels were
normal. Lipid-lowering, antihypertensive and antidiabetic drugs
were started at the discretion of the treating physicians.
General population. Population data were derived from the
Lifelines study [9], a cohort follow-up study in a random sample of
165,000 inhabitants of the northern part of the Netherlands
covering three generations. All participants provided written
informed consent before participating in the study. The medical
ethical review committee of the University Medical Center
Groningen approved the study protocol.
For the present cross-sectional study we included subjects of
Western European origin and age of 18–80 years who participated
between December 2006 and January 2012. The total number of
individuals included was 63,995.
Criteria for the metabolic syndrome
The criteria for the metabolic syndrome as imposed by the
National Cholesterol Education Program Adult Treatment Panel
III, last updated in 2005 by the American Heart Association [10],
were used. These criteria have been extensively evaluated [11,12],
the majority of reports being supportive of the criteria posing a
useful and accurate prediction of cardiovascular risk. Metabolic
syndrome was defined as having any three of the following:
- Waist circumference $102 cm in men and $88 cm in
women. If waist circumference was unknown, patients with a
BMI of over 30.0 kg/m2 were assumed to have an elevated
waist circumference. This threshold serves as a conservative
indication of elevated waist circumference [13], and is used in
the criteria of the International Diabetes Foundation [14].
- Triglycerides $150 mg/dL, or specific drug treatment.
- HDL-cholesterol ,40 mg/dL in men and ,50 mg/dL in
women, or specific drug treatment.
- Blood pressure $130 mmHg systolic or $85 mmHg diastolic,
or antihypertensive treatment.
- Fasting glucose $100 mg/dL, or antidiabetic treatment.
The criteria state that fibrates and nicotinic acid are the most
commonly used drugs for elevated triglycerides and reduced HDL-
cholesterol, implying that statins are not considered specific
treatment for those conditions. Indeed, statins predominantly
lower LDL-cholesterol and have only a minor indirect effect on
triglyceride and HDL-cholesterol levels [15,16]. Therefore, in this
study only fibrates and nicotinic acid were considered specific
treatment for elevated triglycerides or reduced HDL-cholesterol.
Assays
From 1986 to 2005, serum IGF-I concentrations were
determined by RIA (Incstar, Stillwater, USA) with a detection
limit of 1.5 nmol/liter and an interassay CV less than 11%. Since
Metabolic Syndrome in Pituitary Adenomas
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2005, serum IGF-I concentrations (nanomoles/liter) were mea-
sured using an immunometric technique on an Immulite 2500
system (Siemens Healthcare Diagnostics, Deerfield, USA). The
intraassay variations at mean plasma levels of 8 and 75 nmol/liter
were 5.0% and 7.5%, respectively. A Hitachi modular P800
autoanalyzer (Roche Diagnostics, Indianapolis, USA) was used to
quantify fasting serum concentrations of glucose, total cholesterol,
and triglycerides. Fasting serum concentrations of HDL-choles-
terol were measured with a homogenous enzymatic assay (Hitachi
911; Roche).
Statistical analysis
Standardized morbidity ratios were estimated based on
observed and expected number of patients fulfilling the different
metabolic syndrome criteria. Expected numbers were obtained by
indirect standardization, in which population specific morbidity
risks were applied to the number of persons at risk stratified for
gender and age (,30, 30–40, 40–50, 50–60, 60–70, and .70
years old). The 95% confidence interval was calculated by a
shortcut method based on the Poisson distribution [17].
VFD, radiotherapy, and (treated) hypopituitarism (defined as
number of affected axes, 0–4) were tested for their influence on the
different metabolic syndrome criteria using logistic regression. A
minimally adjusted model included age and gender (model 1) or
age, gender and BMI (model 2), to assess the total effect of a given
variable (e.g. radiotherapy), irrespective of its causal pathway. A
maximally adjusted model included age, gender, VFD, radiother-
apy, and hypopituitarism, again without or with BMI (models 3
and 4, respectively), to assess the unmediated direct effect of the
variable. In an additional analysis, hypopituitarism was replaced
by ACTH deficiency, TSH deficiency, GHD, or rhGH replace-
ment (in the GHD patients only). In another analysis, VFD was
replaced by suprasellar tumor extension against the 3rd ventricle
(Hardy-Wilson classification B or C). BMI was included to the
minimal and maximal models separately because it can be
considered both as closely related to waist circumference and
therefore as part of the metabolic syndrome (arguing against
correction), and as a confounding influence to the other
parameters of the metabolic syndrome (arguing for correction).
Results
Clinical characteristics (Table 1)
All 145 NFMA patients (64 women) were treated by transsphe-
noidal surgery for suprasellar extension and were in remission
(considered as absence of or stable residual adenoma) for at least
one year (median 12 yrs, range 1–49 yr). Median age at the time of
current evaluation was 63 years (range 26–88 yrs). Preoperatively,
125 patients (86%) presented with VFD, which improved
considerably after surgery in all patients, although small peripheral
VFD persisted in 55% of patients. These patients did not differ in
gender, age, BMI, radiotherapy use, or substitution therapy from
the 45% that experienced full visual field recovery. Tumor size was
larger than 10 mm in all cases, most often classified as non-
invasive (64%) and extending suprasellarly (in the recesses of the
third ventricle) in 83%. Adjuvant radiotherapy was required in 68
patients (47%) for recurrent or persistent disease. At the time of
evaluation, 92% of patients had one or more pituitary deficiencies.
Specifically, 75% had somatotrope deficiency, 70% corticotrope
deficiency, and 71% thyrotrope deficiency. Gonadotrope deficien-
cy was present in 69% of men and 59% of women (although 53%
of women were postmenopausal at evaluation). All patients were
adequately and stably treated for all pituitary deficiencies, except
for GHD, which was untreated in 27 of 109 GHD patients (25%)
because of contraindications or the patient’s preference. Antihy-
pertensive medication was used by 41% of patients, statins by
35%, and fibrates or nicotinic acid by 1%.
Control data of 63,995 population samples controls (59%
females) were used, with a median age of 45 years (range 18–80
yrs). In this population, 11% used antihypertensive medication,
5% statins, and 0% used fibrates or nicotonic acid.
Prevalence of (components of) the metabolic syndrome
(Figure 1)
Of 145 NFMA patients, elevated waist circumference was
observed in 53.1%, elevated blood pressure in 75.9%, elevated
fasting glucose in 31.7%, reduced HDL-cholesterol in 29.0%, and
elevated triglycerides in 46.9%. Subsequently, 44.1% of patients
were classified as having the metabolic syndrome.
Compared to the general population, NFMA patients showed
increased risk for reduced HDL-cholesterol (SMR 1.59, 95% CI
1.13–2.11), elevated triglycerides (SMR 2.31, 95% CI 1.78–2.90),
and the metabolic syndrome (SMR 1.60, 95% CI 1.22–2.02). No
increased risk for elevated waist circumference, blood pressure, or
glucose levels was observed.






VFD at presentation 125 (86)
Transsphenoidal surgery 145 (100)
Adjuvant radiotherapy 68 (47)
Years post-surgery 12 (1–49)
Body Mass Index{ 27.6 6 4.2
Hardy tumor size
II. .10 mm without invasiveness 93 (64)
III. Localized invasive 32 (22)
IV. Diffuse invasive 20 (14)
Hardy tumor extension
A. Suprasellar cistern 8 (6)
B. Recesses of 3rd ventricle 120 (83)
C. Whole anterior 3rd ventricle 14 (10)
D. Intracranial (intradural) 2 (1)
E. Into or beneath cavernous sinus 37 (26)
One or more pituitary deficiencies 134 (92)
ACTH deficiency 102 (70)
TSH deficiency 104 (71)
LF/FSH deficiency 94 (65)
GH deficiency 109 (75)
Uses rhGH` 82 (75)
Stopped using rhGH` 11 (10)
Antihypertensive use 59 (41)
Statin use 51 (35)
Fibrates or nicotinic acid use 1 (1)
Data represent number (percentage) or median (range). VFD: visual field
defects. rhGH: recombinant human growth hormone. {Data represent average
6 standard deviation. `Percentage within growth hormone deficiency.
doi:10.1371/journal.pone.0090602.t001
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Risk factors for metabolic parameters within the NFMA
cohort (Table 2)
Preoperative VFD were independently associated with elevated
blood pressure in all models (OR1 5.1, 95% CI 1.6–15.7; OR2 5.4,
95% CI 1.7–17.2; OR3 7.4, 95% CI 2.1–26.2; OR4 7.6, 95% CI
2.0–28.2), but no associations were observed with any other
parameter of the metabolic syndrome. Persistence of VFD, and
years after surgery were of no significant influence to the metabolic
parameters in any of the four models (data not shown), and neither
was radiotherapy. When preoperative VFD were replaced with
suprasellar tumor extension against the 3rd ventricle (Hardy-
Wilson classification B or C), no association between suprasellar
extension and any of the parameters was observed.
Hypopituitarism was associated with increased waist circumfer-
ence when corrected only for age and gender (OR1 1.6, 95% CI
1.2–2.2), and with the metabolic syndrome when corrected for age
and gender (OR1 1.4, 95% CI 1.1–1.9), or for age, gender, VFD,
and radiotherapy (OR3 1.4, 95% CI 1.0–1.9). Additional analysis
of deficiency of separate axes, revealed that this association
between hypopituitarism and metabolic parameters could mainly
be attributed to the influence of GHD patients on increased waist
circumference (OR1 6.3, 95% CI 2.5–15.4), reduced HDL-
cholesterol (OR1 3.3, 95% CI 1.7–9.3), and the metabolic
syndrome (OR1 5.0, 95% CI 2.0–12.7), although only in the
minimal model. Within the GHD patients, rhGH replacement was
associated with a BMI-dependent increased odd for increased
waist circumference (OR1 3.3, 95% CI 1.3–8.3; OR3 3.5, 95% CI
1.4–8.8), blood pressure (OR3 3.4, 95% CI 1.0–11.9), and the
metabolic syndrome (OR1 2.5, 95% CI 1.0–6.4; OR3 2.7, 95% CI
1.1–7.0), when compared to the GHD patients without rhGH
replacement. Cortisol substitution was associated with a mildly
decreased odd for decreased HDL-cholesterol in models 3 and 4
(OR3 0.3, 95% CI 0.1–0.9; OR4 0.3, 95% CI 0.1–0.9), and
thyroid hormone substitution with increased waist circumference
(OR2 0.2, 95% CI 0.1–0.6; OR4 0.2, 95% CI 0.0–0.6) and the
metabolic syndrome (OR2 0.4, 95% CI 0.1–1.0) in models that
included correction for BMI.
Discussion
This study demonstrates that patients from an unselected cohort
of patients treated for NFMA have a 60% increased risk for the
metabolic syndrome, mainly due to a 59% increased risk for
reduced HDL-cholesterol and a 131% increased risk for elevated
triglycerides, despite long-term remission.
To date, long-term data on metabolic outcome in exclusively
NFMA cohorts are scarce, and limited to mortality studies. One
study reported no increased cardiovascular or cerebrovascular
mortality in a cohort of 192 adequately substituted NFMA patients
[18], although no individual influences of substitution therapy
were evaluated. Another study observed increased mortality by
cardiovascular and respiratory disease in a cohort of 573 NFMA
patients with variable adequacy of replacement therapy (SMR
1.70, 95% CI 1.34–2.15), although outcome was significantly
better when compared with craniopharyngioma or other causes of
hypopituitarism [19]. Lastly, a meta-analysis including 5412
female hypopituitary patients of heterogeneous origin, both of
childhood and adult onset, but excluding previous GH or ACTH
excess, and with variable adequacy of substitution therapy, found
SMR’s of 1.21–3.80 [20]. Thus, these mortality studies suggest an
adverse metabolic profile in NFMA patients. This study is the first
to assess the prevalence of metabolic syndrome components in a
homogeneous cohort of NFMA patients in which hormone
replacement therapy was administered according to current
guidelines, including rhGH replacement therapy in the majority
of GHD patients.
NFMA patients often present with compression of the optic
chiasm region, potentially also affecting the hypothalamic region.
The hypothalamus is known to play a key role in the regulation of
energy balance [21,22]. In accordance, a syndrome known as
hypothalamic obesity occurs after structural hypothalamic dam-
age, e.g. in craniopharyngioma, after radiotherapy or trauma, and
in genetic disorders such as Prader-Willi syndrome [5]. Several
studies suggest an important role for the hypothalamic SCN in
metabolism, and dysregulation was reported to be associated with
metabolic syndrome in mice, in elderly and in cranial radiotherapy
[23–26]. Furthermore, we previously reported that NFMA
patients show alterations in sleep stages and sleep-wake rhythmic-
ity [4], which are largely influenced by SCN function. Therefore,
although sleep restriction per se is also directly linked to metabolic
parameters [6], the metabolic alterations found in NFMA patients
might be explained by mechanical destruction of hypothalamic
nuclei, specifically the SCN, in addition to intrinsic imperfections
of hormone replacement therapy for hypopituitarism [27] or
untreated GH deficiency.
In the current study, preoperative VFD, indicating compression
of the optic chiasm region, were independently associated with
hypertension. Interestingly, postmortem neuroanatomical assess-
ment of hypertensive patients revealed disturbed SCN structure
[28], and re-entraining the SCN with melatonin in hypertensive
patients allowed the physiological decrease in blood pressure at
night to recur [29]. Melatonin also induces visceral fat loss and
improvement of the metabolic syndrome in rats [30], although
VFD were not associated with central obesity or the metabolic
Figure 1. Comparison of metabolic syndrome prevalence, according to the NCEP-ATP III criteria, between NFMA patients and the
general population. O, observed; E, expected. {according to the NCEP-ATP III [10].
doi:10.1371/journal.pone.0090602.g001
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syndrome in the current study. It is of note that the duration of
compression cannot be accurately evaluated, and that at present it
is not possible to specifically measure hypothalamic function. In
addition, it is not known whether VFD or only radiological
evaluation are a requisite for hypothalamic compression. Howev-
er, a recent post-mortem study in patients with suprasellar tumors
leading to visual field defects reported reduced arginine-vasopres-
sine immunoreactivity in the SCN, when compared to controls
[31]. Notably, the association between suprasellar invasiveness
(through the observation of preoperative VFD) and hypertension
was not observed when a Hardy-Wilson classification of B (against
recesses of 3rd ventricle) or C (whole anterior 3rd ventricle) was
used to define hypothalamic compression. This might be explained
by intra- and inter-observer variation, and the fact that the
position of the compressing tumor relative to the SCN is not taken
into account.
We further explored several factors with possible influence on
(components of) the metabolic syndrome. Number of deficient
pituitary axes (which might indicate larger tumor size) was
associated with an increased odd for abdominal obesity and the
metabolic syndrome, mainly due to the influence of GHD,
although this association was dependent on BMI, VFD, radio-
therapy and other pituitary deficiencies. Importantly, GHD did
not influence the affected triglyceride component in our cohort.
GHD can therefore potentially explain some, but not all of the
metabolic risk in NFMA patients. In addition, we observed an
increased odd for abdominal obesity, hypertension and the
metabolic syndrome for rhGH replacement within GHD patients,
although this might be confounded by treatment indication in this
Table 2. Risk factors for the metabolic syndrome, according to the NCEP-ATPIII criteria, in NFMA patients using four logistic
regression models.
Waist circumference
OR1 OR2 OR3 OR4
VFD 0.9 (0.4–2.4) 0.9 (0.3–3.2) 0.8 (0.3–2.2) 1.1 (0.3–3.7)
RT 1.2 (0.6–2.3) 1.2 (0.5–2.9) 1.0 (0.5–2.0) 1.3 (0.5–3.3)
Hypopit 1.6 (1.2–2.2)* 0.8 (0.5–1.1) 1.6 (0.2–2.2) 0.7 (0.5–1.1)
Fasting glucose
OR1 OR2 OR3 OR4
VFD 1.4 (0.5–4.3) 0.7 (0.2–2.1) 1.4 (0.5–4.1) 1.5 (0.5–4.5)
RT 1.0 (0.5–2.1) 1.0 (0.5–2.1) 1.0 (0.5–2.0) 1.0 (0.5–2.2)
Hypopit 1.2 (0.9–1.6) 0.9 (0.7–1.3) 1.2 (0.9–1.6) 0.9 (0.6–1.3)
Triglycerides
OR1 OR2 OR3 OR4
VFD 0.5 (0.2–1.4) 0.5 (0.2–1.4) 0.5 (0.2–1.3) 0.5 (0.2–1.4)
RT 0.9 (0.5–1.8) 0.9 (0.5–1.8) 0.9 (0.4–1.7) 0.9 (0.5–1.9)
Hypopit 1.2 (0.9–1.6) 1.0 (0.7–1.3) 1.2 (0.9–1.6) 1.0 (0.7–1.3)
Blood pressure
OR1 OR2 OR3 OR4
VFD 5.1 (1.6–15.7)* 5.4 (1.7–17.2)* 5.2 (1.7–16.3)* 6.5 (1.9–22.2)*
RT 0.7 (0.3–1.7) 0.7 (0.3–1.7) 0.7 (0.3–1.8) 0.8 (0.3–2.0)
Hypopit 1.0 (0.7–1.3) 0.7 (0.5–1.1) 1.0 (0.7–1.3) 0.7 (0.4–1.0)
HDL – cholesterol
OR1 OR2 OR3 OR4
VFD 0.9 (0.3–2.6) 0.9 (0.3–2.5) 0.9 (0.3–2.5) 0.9 (0.3–2.7)
RT 1.6 (0.8–3.2) 1.6 (0.8–3.4) 1.5 (0.7–3.1) 1.7 (0.8–3.6)
Hypopit 1.2 (0.9–1.6) 0.9 (0.6–1.3) 1.2 (0.9–1.6) 0.9 (0.6–1.3)
Metabolic syndrome{
OR1 OR2 OR3 OR4
VFD 2.0 (0.7–5.6) 2.4 (0.7–7.6) 1.8 (0.6–5.2) 2.6 (0.8–8.5)
RT 1.4 (0.7–2.7) 1.6 (0.7–3.5) 1.3 (0.7–2.6) 1.7 (0.8–3.9)
Hypopit 1.4 (1.1–1.9)* 0.8 (0.6–1.2) 1.4 (1.0–1.9)* 0.7 (0.5–1.1)
Data represent odds ratio (95% confidence interval). RT, radiotherapy; VFD, visual field defects at presentation; Hypopit, hypopituitarism (number of deficient pituitary
axes). OR1: regression model 1 (age and gender). OR2: regression model 2 (age, gender, BMI). OR3: regression model 3 (age, gender, VFD, RT, hypopit). OR4: regression
model 4 (age, gender, VFD, RT, Hypopit, BMI). {according to the NCEP-ATP III [10]. *difference statistically significant (P # 0.05).
doi:10.1371/journal.pone.0090602.t002
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cross-sectional analysis. In previous studies, associations between
untreated GHD and increased prevalence of dyslipidemia,
hypertension, abdominal obesity and the metabolic syndrome
were observed [32–34]. RhGH treatment improved dyslipidemia,
hypertension and obesity in many [32,35], but not all [34,36]
studies, and insulin sensitivity decreased in some studies [34–36].
The results in our cohort of NFMA patients were therefore
partially in line with reports in GHD cohorts, although those
studies are difficult to compare due to large heterogeneity.
In our cohort, glucocorticoid replacement was associated with a
mildly decreased prevalence of lower HDL, but had no effect on
the metabolic syndrome. Previous studies reported increased
prevalence of the metabolic syndrome in mildly increased cortisol
levels of overtreated NFMA patients [37]. All patients in our
cohort were, however, stably and adequately substituted for
ACTH deficiency at the lowest dose considered adequate on a
daily basis (mean 20.764.2 mg). Radiotherapy and TSH
deficiency did not influence components of the metabolic
syndrome in our cohort.
Several limitations of the study need to be discussed. Patients
with sufficient data were selected from a pre-existing database,
inducing the possibility of a selection bias. For instance, metabolic
parameters are in general more frequently evaluated in GHD
patients, increasing their chance of being included. Correcting for
hormonal deficiencies in the regression analysis minimalized this
bias. Also, the cross-sectional design of this study did not allow us
to study incidence and mortality rates, although we previously
reported nonsignificantly increased overall mortality in 172
NFMA patients in our institution (SMR 1.24, 95% CI 0.85–
1.74) [38]. Another limitation is the definition or classification of
risk factors, e.g. for pituitary function, treatment modality and
having a history of hypothalamic compression. Also, we did not
correct for the number of years after radiotherapy or after start of
rhGH, since patients were considered to be in a stable situation
and the most dramatic effects of those treatments are observed in
the short-term. However, their effect on the long-term might still
influence the metabolic outcome to some extent, although not
significantly in this study. Next, inherent to stratification is the
chance of residual confounding. Within the strata, patients were
statistically significantly older than the general population in age-
groups 50–60 years (54.762.8 vs. 53.863.1, P=0.05) and .70
years (76.364.7 vs. 73.762.7, P,0.001), although the clinical
relevance of these differences can be considered small. Next, in this
unselected cohort, most patients had tumors with supersellar
tumor extension, as indicated by the prevalent preoperative VFD
(86%) or Hardy’s classification B or C (93%). This uneven
distribution might have limited the statistical power to assess
differences in metabolic outcome caused by suprasellar extension.
Lastly, we chose not to include statin use in the criteria for the
metabolic syndrome, as directed in the official statement [10].
Consequently, since statins have a small beneficial effect on
triglycerides and HDL, and statin use was higher in NFMA
patients than controls (35% vs. 5.3%), it is likely that the results of
this study underestimate the actual risk for the metabolic
syndrome and represent a rather conservative estimation of the
magnitude of the metabolic disadvantages that come with a history
of NFMA.
In conclusion, patients treated for NFMA are at increased risk
of having the metabolic syndrome, in particular dyslipidemia. This
was only partly explained by hypopituitarism or hormone
replacement therapy. Further study is required to determine
which processes are involved in this patient group, e.g. by assessing
alterations in circadian activity, food intake, or energy expendi-
ture. The results of this study advocate stringent control and
treatment of cardiovascular risk factors, like in patients with
prevalent diseases at increased cardiovascular risk.
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